Celldex Therapeutics, Inc.
https://www.celldex.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Celldex Therapeutics, Inc.
Japan Pricing Update: Wegovy Finally Listed, Upcoming Special Cuts For Imfinzi, Polivy
Japan adds a batch of new drugs, including Wegovy, to the national health insurance reimbursement tariff, but discussions over Leqembi for Alzheimer’s are still ongoing, with indications that repricing could be possible if demand expands quickly.
Finance Watch: CARGO Gets A Lukewarm Reception After Stock Market Debut
Public Company Edition: CARGO Therapeutics grossed $281.3m, giving it the fifth-largest biopharma IPO this year. Also, Alkermes completed its cancer business spinout as Mural Oncology, which launched with $275m, and Xencor sold Ultomiris and Monjuvi royalties for $215m.
Finance Watch: $1.3bn In New Venture, Equity Capital Across Three New Funds
Private Company Edition: Revelation Partners amassed $608m, Bioluminescence Ventures emerged with $477m and Abingworth raised $356m for late-stage programs. In recent financings, MapLight closed a $225m series C round while Triveni launched with $92m and Gate garnered $60m in series A rounds.
GSK’s IO Backbone Jemperli Looks Stronger After OS Success
Jemperli has struggled to gain a presence in cancer immunotherapy so far, but GSK believes the PD-1 therapy can hold its own against Merck & Co’s mega-blockbuster Keytruda in a few key areas.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Other Names / Subsidiaries
-
- Avant Immunotherapeutics, Inc.
- CuraGen Corporation
- Kolltan Pharmaceuticals, Inc.
- Xetrios Therapeutics Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice